{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,27]],"date-time":"2026-03-27T19:19:01Z","timestamp":1774639141511,"version":"3.50.1"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T00:00:00Z","timestamp":1734307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neoplasia"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.neo.2024.101108","type":"journal-article","created":{"date-parts":[[2024,12,25]],"date-time":"2024-12-25T16:10:10Z","timestamp":1735143010000},"page":"101108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma"],"prefix":"10.1016","volume":"60","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4581-8167","authenticated-orcid":false,"given":"Jeannette C.","family":"Oosterwijk-Wakka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liesbeth","family":"Houkes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3914-7491","authenticated-orcid":false,"given":"Loes F.M.","family":"van der Zanden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lambertus A.L.M.","family":"Kiemeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Junker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1170-7867","authenticated-orcid":false,"given":"Anne Y","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Eisen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2493-7370","authenticated-orcid":false,"given":"Ulrich","family":"Jaehde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marius T","family":"Radu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rob","family":"Ruijtenbeek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5049-0018","authenticated-orcid":false,"given":"Egbert","family":"Oosterwijk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neo.2024.101108_bib0001","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.eururo.2014.10.002","article-title":"International variations and trends in renal cell carcinoma incidence and mortality","volume":"67","author":"Znaor","year":"2015","journal-title":"Eur. Urol"},{"key":"10.1016\/j.neo.2024.101108_bib0002","doi-asserted-by":"crossref","first-page":"371","DOI":"10.2147\/OTT.S123061","article-title":"Overall survival in renal cell carcinoma after introduction of targeted therapies: a Norwegian population-based study","volume":"10","author":"Beisland","year":"2017","journal-title":"Onco. Targ. Ther"},{"issue":"1","key":"10.1016\/j.neo.2024.101108_bib0003","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/annonc\/mdv504","article-title":"Treatment patterns and clinical outcomes in patients with renal cell carcinoma in the UK: insights from the RECCORD registry","volume":"27","author":"Wagstaff","year":"2016","journal-title":"Ann. Oncol"},{"key":"10.1016\/j.neo.2024.101108_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.03.006","article-title":"European association of urology guidelines on renal cell carcinoma: the 2022 update","author":"Ljungberg","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.neo.2024.101108_bib0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.eururo.2017.11.016","article-title":"Updated European association of urology guidelines: recommendations for the treatment of first-line metastatic clear cell renal cancer","volume":"73","author":"Powles","year":"2018","journal-title":"Eur. Urol"},{"issue":"21","key":"10.1016\/j.neo.2024.101108_bib0006","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16213689","article-title":"Prognostic value of neutrophil-to-eosinophil ratio (NER) in cancer: a systematic review and meta-analysis","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.neo.2024.101108_bib0007","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16101835","article-title":"Prognostic significance of the royal marsden hospital (RMH) score in patients with cancer: a systematic review and meta-analysis","volume":"16","author":"Sahin","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"7","key":"10.1016\/j.neo.2024.101108_bib0008","article-title":"Whole-exome sequencing (WES) predicting two extreme phenotypes of response to VEGF-targeted therapies (VEGF-TT) in patients with metastatic clear cell renal cell carcinoma (mRCC)","volume":"33","author":"Fay","year":"2015","journal-title":"J. Clin. Oncol"},{"issue":"37","key":"10.1016\/j.neo.2024.101108_bib0009","doi-asserted-by":"crossref","first-page":"59070","DOI":"10.18632\/oncotarget.10887","article-title":"The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma","volume":"7","author":"Goto","year":"2016","journal-title":"Oncotarget"},{"issue":"5","key":"10.1016\/j.neo.2024.101108_bib0010","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.ccell.2016.03.004","article-title":"Exosome-transmitted lncARSR promotes sunitinib resistance in renal cancer by acting as a competing endogenous RNA","volume":"29","author":"Qu","year":"2016","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.neo.2024.101108_bib0011","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.bbrc.2016.03.048","article-title":"Decreased apoptosis repressor with caspase recruitment domain confers resistance to sunitinib in renal cell carcinoma through alternate angiogenesis pathways","volume":"473","author":"Gobe","year":"2016","journal-title":"Biochem. Biophys. Res. Commun"},{"issue":"4","key":"10.1016\/j.neo.2024.101108_bib0012","first-page":"E191","article-title":"Expression level of Gli2 in radical nephrectomy specimens as a prognostic predictor in patinets with metastatic renal clear cell carcinoma treated with sunitinib","volume":"189","author":"Furukawa","year":"2013","journal-title":"J Urology"},{"issue":"1","key":"10.1016\/j.neo.2024.101108_bib0013","first-page":"1","article-title":"Resistance to sunitinib in renal cell carcinoma: from molecular mechanisms to predictive markers and future perspectives","volume":"1855","author":"Joosten","year":"2015","journal-title":"Biochim. Biophys. Acta"},{"issue":"9","key":"10.1016\/j.neo.2024.101108_bib0014","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0139267","article-title":"High throughput kinomic profiling of human clear cell renal cell carcinoma identifies kinase activity dependent molecular subtypes","volume":"10","author":"Anderson","year":"2015","journal-title":"PLoS One"},{"issue":"41","key":"10.1016\/j.neo.2024.101108_bib0015","doi-asserted-by":"crossref","first-page":"67507","DOI":"10.18632\/oncotarget.11686","article-title":"Clinical and kinomic analysis identifies peripheral blood mononuclear cells as a potential pharmacodynamic biomarker in metastatic renal cell carcinoma patients treated with sunitinib","volume":"7","author":"Noe","year":"2016","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.neo.2024.101108_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.urolonc.2017.03.009","article-title":"Description of the EuroTARGET cohort: a European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity","volume":"35","author":"van der Zanden","year":"2017","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.neo.2024.101108_bib0017","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S1470-2045(12)70559-4","article-title":"External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study","volume":"14","author":"Heng","year":"2013","journal-title":"Lanc. Oncol"},{"issue":"3","key":"10.1016\/j.neo.2024.101108_bib0018","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S1470-2045(14)71222-7","article-title":"The international metastatic renal cell carcinoma database consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study","volume":"16","author":"Ko","year":"2015","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.neo.2024.101108_bib0019","doi-asserted-by":"crossref","first-page":"e89449","DOI":"10.1371\/journal.pone.0089449","article-title":"The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma","volume":"9","author":"Grepin","year":"2014","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.neo.2024.101108_bib0020","doi-asserted-by":"crossref","first-page":"2476","DOI":"10.1016\/j.celrep.2016.02.024","article-title":"Multilevel genomics-based taxonomy of renal cell carcinoma","volume":"14","author":"Chen","year":"2016","journal-title":"Cell Rep"},{"issue":"7456","key":"10.1016\/j.neo.2024.101108_bib0021","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/nature12222","article-title":"Cancer genome atlas research N. Comprehensive molecular characterization of clear cell renal cell carcinoma","volume":"499","year":"2013","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.neo.2024.101108_bib0022","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/ng.2699","article-title":"Integrated molecular analysis of clear-cell renal cell carcinoma","volume":"45","author":"Sato","year":"2013","journal-title":"Nat. Genet"},{"issue":"2","key":"10.1016\/j.neo.2024.101108_bib0023","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1177\/1947601909359929","article-title":"Molecular stratification of clear cell renal cell carcinoma by consensus clustering reveals distinct subtypes and survival patterns","volume":"1","author":"Brannon","year":"2010","journal-title":"Genes Canc"},{"issue":"6","key":"10.1016\/j.neo.2024.101108_bib0024","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1158\/1078-0432.CCR-14-1128","article-title":"Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting","volume":"21","author":"Beuselinck","year":"2015","journal-title":"Clin. Can. Res"},{"key":"10.1016\/j.neo.2024.101108_bib0025","doi-asserted-by":"crossref","first-page":"970","DOI":"10.18632\/oncotarget.28257","article-title":"Kinase activity profiling in renal cell carcinoma, benign renal tissue and in response to four different tyrosine kinase inhibitors","volume":"13","author":"Tahiri","year":"2022","journal-title":"Oncotarget"},{"issue":"10","key":"10.1016\/j.neo.2024.101108_bib0026","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1113205","article-title":"Intratumor heterogeneity and branched evolution revealed by multiregion sequencing","volume":"366","author":"Gerlinger","year":"2012","journal-title":"N Engl. J. Med"},{"issue":"11\u201312Suppl7","key":"10.1016\/j.neo.2024.101108_bib0027","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.5489\/cuaj.4315","article-title":"Sunitinib side effects as surrogate biomarkers of efficacy","volume":"10","author":"Kollmannsberger","year":"2016","journal-title":"Can. Urol. Assoc. J"},{"issue":"2","key":"10.1016\/j.neo.2024.101108_bib0028","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/CAD.0000000000000439","article-title":"Prognostic role of the cumulative toxicity in patients affected by metastatic renal cells carcinoma and treated with first-line tyrosine kinase inhibitors","volume":"28","author":"Iacovelli","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"3","key":"10.1016\/j.neo.2024.101108_bib0029","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.cell.2018.03.043","article-title":"Deterministic evolutionary trajectories influence primary tumor growth: TRACERx Renal","volume":"173","author":"Turajlic","year":"2018","journal-title":"Cell"},{"issue":"7329","key":"10.1016\/j.neo.2024.101108_bib0030","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1038\/469156a","article-title":"Bring on the biomarkers","volume":"469","author":"Poste","year":"2011","journal-title":"Nature"}],"container-title":["Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624001490?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476558624001490?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,4]],"date-time":"2025-03-04T08:45:28Z","timestamp":1741077928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476558624001490"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"alternative-id":["S1476558624001490"],"URL":"https:\/\/doi.org\/10.1016\/j.neo.2024.101108","relation":{},"ISSN":["1476-5586"],"issn-type":[{"value":"1476-5586","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Kinomic profiling to predict sunitinib response of patients with metastasized clear cell Renal Cell Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neo.2024.101108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"101108"}}